Reprogenetics, Illumina Team Up to Use Next-Gen Sequencing Technology for Infertility

Livingston, N.J. diagnostic products maker Reprogenetics is partnering with Illumina to use next-generation sequencing capabilities in the development of in vitro fertilization systems.

Under the agreement, Reprogenetics will use Illumina's VeriSeq NGS technology to screen all 24 chromosomes to identify embryos with the greatest potential to produce a viable pregnancy. The two companies will evaluate the technology via randomized clinical trials in the U.S. and UK of patients eligible for chromosome screening.

According to Tristan Orpin, vice president of Illumina, VeriSeq offers improved assay workflow, higher throughput and enhanced performance — complementing Reprogenetics' portfolio by streamlining and improving the preimplantation genetic screening process. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.